Enanta Pharmaceuticals, Inc.
Records under this name other than the patents Enanta Pharmaceuticals, Inc. holds now: patents now held by others, patents whose terms have ended, and its applications, pending or abandoned. None of them is counted in the 144 patents it holds.
Back to Enanta Pharmaceuticals, Inc.
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 8,420,596 | Macrocyclic Hepatitis C Serine Protease Inhibitors Formerly held In force · High confidence | In force | High confidence | |
| US 9,493,506 | Macrocyclic Hepatitis C Serine Protease Inhibitors Formerly held In force · Medium confidence | In force | Medium confidence | |
| US 8,748,374 | Macrocyclic Hepatitis C Serine Protease Inhibitors Formerly held In force · High confidence | In force | High confidence | |
| US 8,951,964 | Phenanthridine Macrocyclic Hepatitis C Serine Protease Inhibitors Formerly held In force · High confidence | In force | High confidence | |
| US 11,466,033 | Substituted Pyridines as Apoptosis Signal-Regulating Kinase 1 Inhibitors Lapsed on the fee record Ended Oct 11, 2026 · High confidence | Lapsed on the fee record | Ended Oct 11, 2026 | High confidence |
| US 8,846,638 | Macrocyclic Nucleoside Phosphoramidate Derivatives Lapsed on the fee record Ended Sep 30, 2026 · High confidence | Lapsed on the fee record | Ended Sep 30, 2026 | High confidence |
| US 10,080,741 | Isoxazole Derivatives as FXR Agonists and Methods of Use Thereof Lapsed on the fee record Ended Sep 25, 2026 · High confidence | Lapsed on the fee record | Ended Sep 25, 2026 | High confidence |
| US 10,080,742 | Isoxazole Derivatives as FXR Agonists and Methods of Use Thereof Lapsed on the fee record Ended Sep 25, 2026 · High confidence | Lapsed on the fee record | Ended Sep 25, 2026 | High confidence |
| US 10,080,743 | Isoxazole Derivatives as FXR Agonists and Methods of Use Thereof Lapsed on the fee record Ended Sep 25, 2026 · High confidence | Lapsed on the fee record | Ended Sep 25, 2026 | High confidence |
| US 8,815,928 | Hepatitis C Virus Inhibitors Lapsed on the fee record Ended Aug 26, 2026 · High confidence | Lapsed on the fee record | Ended Aug 26, 2026 | High confidence |